Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

A Second Controversial Duchenne Approval For Company

 
• By Andrew McConaghie
FDAEntrance_1200x675
The approval went through the newly reorganized FDA Office of New Drugs

More from New Products

More from Scrip